Shandong Weigao Group Medical Polymer Company Limited (Weigao Group) disclosed a small-scale buyback of its Hong Kong-listed H-shares under the Next Day Disclosure Return filed on 20 July 2026.

On 20 July 2026, the company repurchased 40,000 H-shares on the Stock Exchange of Hong Kong at a fixed price of HKD 3.44 per share, totalling HKD 137,600. The bought-back shares have been retained as treasury stock.

Key post-transaction metrics: • Issued shares (excluding treasury stock) fell marginally by 0.0009% to 4,460.85 million shares. • Treasury share balance increased to 61.48 million shares. • Total shares in issue remained unchanged at 4,522.33 million shares, as the repurchased shares have not been cancelled.

Repurchase mandate status: • Current mandate, approved on 29 May 2026, authorises the company to buy back up to 446.46 million shares. • Cumulative buybacks under this mandate now stand at 4.16 million shares, equivalent to 0.93% of the issued share base at the mandate date. • In line with Hong Kong listing rules, Weigao Group is restricted from issuing new shares or disposing of treasury shares until 19 August 2026.

The company confirmed that the repurchase complied with all relevant regulations and that funds for the transaction have been fully settled.